J&J teams up with TB Alliance to develop tuberculosis drug


NEW YORK Drug developer Johnson & Johnson announced plans to team up with the Global Alliance for Tuberculosis Drug Development as it continues developing the TB treatment TMC207.

As of now, TMC207 is in mid-stage clinical trials and, if approved, could be the first of its kind on the market, as well as the first TB drug in more than four decades to take a new approach to treating the condition, according to reports.

According to the partnership with the TB Alliance, J&J’s partner Tibotec will continue developing the drug for drug-resistant forms of TB. If it is approved, the parties involved will establish an access program for developing countries. The TB Alliance will have a royalty-free license on the drug for drug-susceptible forms of TB and development costs will be shared.

According to the World Health Organization, approximately one-third of the world’s population is infected with bacillus that causes TB. The disease is responsible for nearly 5,000 deaths daily worldwide, making it one of the world’s deadliest diseases.

This ad will auto-close in 10 seconds